WBB Securities initiated coverage on shares of Celularity (NASDAQ:CELU – Free Report) in a research report report published on Monday, Marketbeat reports. The brokerage issued a moderate buy rating and a $6.00 price objective on the stock.
Separately, Wall Street Zen raised shares of Celularity to a “sell” rating in a report on Saturday, August 2nd.
Check Out Our Latest Report on CELU
Celularity Stock Performance
Hedge Funds Weigh In On Celularity
Several institutional investors and hedge funds have recently made changes to their positions in CELU. Acadian Asset Management LLC bought a new position in shares of Celularity during the 1st quarter valued at $34,000. XTX Topco Ltd boosted its position in Celularity by 106.4% during the 2nd quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock valued at $42,000 after buying an additional 11,057 shares during the period. Bank of America Corp DE boosted its position in Celularity by 1,538.1% during the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock valued at $73,000 after buying an additional 35,023 shares during the period. Two Sigma Investments LP purchased a new stake in Celularity during the 4th quarter valued at $93,000. Finally, Valmark Advisers Inc. purchased a new stake in Celularity during the 2nd quarter valued at $98,000. Institutional investors own 19.02% of the company’s stock.
About Celularity
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.
Further Reading
- Five stocks we like better than Celularity
- What Are the U.K. Market Holidays? How to Invest and Trade
- Lowe’s Builds Value for Investors: Still a Good Buy in 2025
- What Investors Need to Know About Upcoming IPOs
- Jackson Hole 2025: Fed’s Signal Could Shift Stocks Fast
- The 3 Best Retail Stocks to Shop for in August
- Rocket Lab Stock: Breakout Brewing or Time for Patience?
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.